Advanced Soft Tissue Sarcoma: Current and Future

Slides:



Advertisements
Similar presentations
A pooled analysis of the final results of the two randomized phase II studies comparing Gemcitabine (G) vs Gemcitabine + Docetaxel (G+D) in patients (pts)
Advertisements

Introduction Discussion CT abdomen 3/3/06 lightheadedness and watery diarrhea. TSH was again less than 0.01, and ACTH less than 5. AST and ALT were 240.
IMPACT OF CHEMOTHERAPY IN UTERINE SARCOMA (UTS): REVIEW OF 12 CLINICAL TRIALS FROM EORTC INVOLVING ADVANCED UTS COMPARED TO OTHER SOFT TISSUE SARCOMA (STS)
Introduction  Soft Tissue Sarcoma (STS) are a group of highly chemotherapy resistant tumors  Doxorubicin is the only APPROVED 1 st line chemotherapy.
Targeting Tumors Using Endogenous Albumin
Systemic therapy More recent agents: Unregistered agents:
Randomized phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas (TRS) Sant P. Chawla,
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
Treatment for metastatic bladdercancer (chemotherapy&radiotherapy) Dr.Mina Tajvidi oncologist.
Outcome of chemotherapy in synovial sarcoma (sys) patients (pts): review of 15 clinical trials from EORTCc involving advanced sys compared to other Soft.
Clinical Case Nº2 Dr. Javier Martín-Broto. Case description 49-year-old man 1 st symptom/sign: Mild pain in right buttock 1 st diagnosis: Core-biopsy:
Symposium 2: Sarcoma of the Year – Synovial Sarcoma Peter Reichardt HELIOS Klinikum Berlin-Buch / Sarcoma Center Berlin-Brandenburg.
12 th Annual CTOS Meeting 2006 AP23573 Induced Long-term Stability in 2 Patients with Desmoplastic Small Round Cell Tumor (#561) Scott Schuetze, Warren.
EORTC OSN/CTOS11 Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final.
Priority of SARC studies for selected sub-types. Eligibility SARC 003 –Gem/docetaxel –Osteo/Ewings < 2 prior regimens –Chondrosarcoma 0-X prior regimens.
The Next Generation of Treatments for Advanced Soft Tissue Sarcomas Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical.
12 th Annual CTOS Meeting 2006 SINGLE AGENT DOXORUBICIN VS DOSE INTENSIVE COMBINATION THERAPY WITH EPIRUBICIN / IFOSFAMIDE IN PREVIOUSLY UNTREATED ADULT.
Biology of Sarcomas “The first thing that the general medical oncologist has to realize is that the parallel word to sarcoma is actually carcinoma,
CCO Independent Conference Coverage
Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)
The Next Generation of Treatments for Advanced Soft Tissue Sarcomas
Precision Medicine: The Potential for Identifying Personalized Therapies for Patients with Gastro-Esophageal Cancer.
Triple-Negative and BRCA-Mutated Metastatic Breast Cancer
Surrogate endpoints in cancer randomized controlled trials:
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.
Presented By Luca Malorni at 2017 ASCO Annual Meeting
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Metastatic HER2+ Breast Cancer: Resistance
Evolving Paradigms in the Management of HR-Positive Breast Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
Patient Case 1 Patient Case 1: PET/CT Scan.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
Non-GIST Soft Tissue Sarcoma: Biology and Basics of Targeted Therapy
Advanced NSCLC Without Actionable Mutations
Her2-positive breast cancer: updating current best practice
Metastatic Renal Cell Carcinoma
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.
Barrios C et al. SABCS 2009;Abstract 46.
Investigación en Sarcomas GEIS Spanish Sarcoma Research Group
Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.
What's on the Horizon for Soft Tissue Sarcoma?
CDK4/6 Inhibitors in Breast Cancer:
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
Volume 15, Issue 4, Pages (April 2014)
Opportunities and Challenges in the Management of Advanced STS
Hormone Receptor-Positive Advanced Breast Cancer:
Expert Insights Into the Latest Treatment of Advanced Soft-Tissue Sarcoma.
Personalizing Management in the Care of Patients With Advanced Sarcoma
Grupo Español de Investigación en Sarcomas
Locally Advanced Lung Cancer
Hormone Receptor-Positive Advanced Breast Cancer Introduction
Introduction Advanced Hormone Receptor-Positive Breast Cancer
Selecting and Applying Chemotherapy
New Paradigms in HR-Positive Advanced Breast Cancer
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
Practical Guidance on the Management of Pan-Negative NSCLC
Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Volume 18, Issue 10, Pages (October 2017)
CDK4/6 Inhibitors.
Taking a Closer Look at Recurrent/Metastatic SCCHN
Real-World Evidence.
Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.
Clinical Focus.
Updates in Sarcoma Benjamin Powers, MD June 2019.
RESULTS BACKGROUND METHODS RESULTS CONCLUSIONS CONTACT
Presentation transcript:

Advanced Soft Tissue Sarcoma: Current and Future

Program Introduction

Sarcoma Histologic Subtypes

Molecular Subtypes of Sarcoma

Histology Subtypes

Drugs and Subtypes

Advanced STS: Mono vs Poly Chemotherapy

Doxorubicin vs Intensified Doxorubicin Plus Ifosfamide for Advanced STS: Phase 3

Gemcitabine Plus Docetaxel vs Doxorubicin as First-Line Therapy in Metastatic STS: Phase 3 GeDDis Trial

Systemic Therapies for Advanced Pretreated STS

Trabectedin vs Dacarbazine in Advanced LMS and LPS: SAR-3007

Eribulin vs Dacarbazine: Phase 3 Trial

Pazopanib for Metastatic STS: Phase 3 PALETTE Trial

Pazopanib in Advanced and/or Metastatic LPS: Phase 2 GEIS-30/GISG-07

PDGFR

PFS for Olaratumab + Doxorubicin vs Doxorubicin Alone (ITT Population)

OS for Olaratumab + Doxorubicin vs Doxorubicin Alone (ITT Population)

Olaratumab Safety

Molecular Subtypes of Sarcoma

M-CSFR Inhibitors in PVNS With t(1,2)

Effect of RG7112 on the p53 Pathway in MDM-2 Amplified Advanced WD/DD LPS

Palbociclib in CDK4 Amplified Advanced WD/DD LPS

Conclusions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.